ADX-038, a Long-Acting CFB siRNA Therapeutic for Multiple Complement Mediated Diseases
Time: 3:00 pm
day: End of Day Two
Details:
- Exploring the current shift towards their use as add-on therapies in hematology where C5 inhibition alone is rarely sufficient
- Delving into the strategic decisions for Factor B when used in addition to expensive C5 inhibitors
- Exploring the current shift towards their use as add-on therapies in hematology where C5 inhibition alone is rarely sufficient
